Alpha Teknova (TKNO) investor relations material

Business overview and market position

• Achieved $40.5 million in 2025 revenue with 7% growth and over 3,000 active customers, including major biopharma accounts.

• 24% of revenue comes from cell and gene therapy, with significant milestones expected in 2026–2027, including supporting commercialized therapeutics and diagnostics.

• 50% of business is biopharma, 30% tools and diagnostics, and 15% from a diverse long tail of customers; 5% of revenue is non-product (services, fees).

• Lab Essentials (research-use-only products) make up 75% of revenue, with 80% of that from catalog products and 15% from custom research products.

• Clinical Solutions (GMP custom products) account for 20% of revenue, with 90% of this segment being custom formulations for clinical manufacturing.

Operational strengths and differentiation

• Ability to migrate customers from catalog to custom and GMP products increases average spend and customer lifetime value.

• Specializes in small, custom batch production with rapid turnaround, outperforming larger competitors in flexibility and speed.

• Dynamic capacity allows seamless switching between catalog and custom production, maximizing manufacturing utilization.

• Proprietary IT systems and internal engineering enable scalable operations up to $200 million in revenue.

• 30 years of know-how in formulation and supply chain management supports rapid, reliable delivery of custom products.

Growth drivers and financial outlook

• Clinical customer base grew 25% to 60, supporting over 70 therapies in clinical trials; five therapies in phase II/III, with at least one expected to commercialize by end of 2027.

• Lab Essentials business is highly diversified, with top 10 customers representing only 18% of revenue and consistent 11% annual growth since 2008.

• New GMP production facility and IT infrastructure support growth to $200 million revenue with minimal additional capital.

• Workforce reduced by 50% since 2022, narrowing losses; expects to reach adjusted EBITDA positive by end of 2027 at $52–$57 million annual revenue.

• Each new revenue dollar yields about 70% gross margin; margins projected to reach 60–65% as scale increases.